Medivir AB (publ) (STO:MVIR)

Market Cap	193.15M
Revenue (ttm)	3.98M
Net Income (ttm)	-97.92M
Shares Out	112.17M
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	186,132
Average Volume	145,663
Open	1.920
Previous Close	1.920
Day's Range	1.878 - 1.932
52-Week Range	1.060 - 3.990
Beta	-0.30
RSI	48.01
Earnings Date	Aug 21, 2025

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MVIR

Financial Performance

In 2024, Medivir AB's revenue was 3.48 million, a decrease of -54.36% compared to the previous year's 7.63 million. Losses were -123.32 million, 38.1% more than in 2023.